This document is a publication of a United States patent application (US20260083672A1) filed by 4TEEN4 Pharmaceuticals GmbH. The application pertains to novel formulations and specific dosage amounts for administering an anti-DPP3 antibody or a fragment thereof to human patients. The stated purpose includes the treatment of severe medical conditions, specifically life-threatening circulatory failure conditions like shock.

As a patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property rights and advancements in the development of therapeutic antibodies. Companies operating in the pharmaceutical and biotechnology sectors, particularly those involved in antibody development or the treatment of shock and circulatory failure, should be aware of this filing as it may impact their research and development strategies or competitive landscape.